Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Kuhle, Jens  [Clear All Filters]
2020
Mimpen M, Muris A-H, Rolf L, Gerlach O, Kuhle J, Hupperts R, Smolders J, Damoiseaux J. Prognostic value of NK cell/ T cell ratios for disease activity in multiple sclerosis. Eur J Neurol. 2020.
2022
Manfredi-Lozano M, Leysen V, Adamo M, Paiva I, Rovera R, Pignat J-M, Timzoura FEzzahra, Candlish M, Eddarkaoui S, Malone SA, et al. GnRH replacement rescues cognition in Down syndrome. Science. 2022;377(6610):eabq4515.
2023
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, et al. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. JAMA Neurol. 2023;80(7):702-713.
Sy M, Newton BL, Pawling J, Hayama KL, Cordon A, Yu Z, Kuhle J, Dennis JW, Brandt AU, Demetriou M. N-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trial. J Neuroinflammation. 2023;20(1):209.
2024
Rusche T, Yaldizli Ö, Galbusera R, Mutke M, Halter JP, Lieb J, Matteazzi F, Stelmes A, Bittner J, Grzonka P, et al. Anti-GABA receptor encephalitis 14 months after allogeneic haematopoietic stem-cell transplant for acute myeloid leukaemia. Lancet. 2024;403(10425):469-470.
Fischbach F, Richter J, Pfeffer LKristina, Fehse B, Berger SCarolina, Reinhardt S, Kuhle J, Badbaran A, Rathje K, Gagelmann N, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024.